viewTHC Global Group Ltd

THC Global products will be more affordable and accessible through Tetra Health acquisition

Canndeo’s recently launched full spectrum CBD medicine is now available for prescription and supply within Tetra Health’s prescriber and pharmacy network.

THC Global Group Ltd - Thc Global Group moves products more affordable and accessible with the acquisition of Tetra Health
Tetra has a database of more than 10,000 prospective clients

THC Global Group Ltd (ASX:THC) has completed the acquisition of Tetra Health, a leading Australian clinic network facilitating access to legal medicinal cannabis medicines for Australian patients.

This will see THC's Canndeo’s medicinal cannabis products available through Tetra's network of more than 600 referring physicians, 30 prescribing physicians and dispensing pharmacies.

THC securities have been almost 8% higher to 42 cents intra-day and the shares are up from 19.5 cents at close on March 30.

Increasing accessibility

Tetra Health chief operating officer Diandra Phipps said: “We are delighted to introduce THC Global’s wholly Australian sourced CBD medicine to our existing product range.

“In the last month, we’ve seen a 40% increase in new patients as we have temporarily reduced our treatment fees, reflecting the current economic conditions.

“With the further reduction in patient costs with THC Global’s full-spectrum CBD medicines launch, Tetra is expecting to deliver a significant increase in patient accessibility to medicinal cannabis medicines in Australia.”

Initially, Canndeo’s full-spectrum CBD range will be available, with the expansion of additional products as they are launched.

Affordable and accessible

Affordability and accessibility remain key barriers to patient uptake of medicinal cannabis within Australia.

Tetra has a database of more than 10,000 prospective patients with 1,000 currently prescribed medicinal cannabis thus offering a low-cost option for patients looking to consider medicinal cannabis, with low-cost consultations and referral options for their existing doctors.

More than 45% of Tetra’s patients using a cannabidiol (CBD) dominant medicine and by combining quality with affordability with its Canndeo range of medicines, THC Global expects patient uptake to increase significantly.

With the recent launch of its first full-spectrum CBD medicine and the new CBD isolate medicine expected in the coming weeks, the company anticipates its products will be highly attractive to Australian patients and prescribers.

Real-world data

In addition to facilitating the legal access to medicinal cannabis medicines for Australian patients, Tetra Health also collects highly sought-after real-world evidence through the patient onboarding and management process.

The data will assist THC Global in making data-driven product decisions, as well as actionable treatment insights to assist in clinical trials or observational study designs enhancing the safety and efficacy data on these medicines.

THC Global anticipates this will further the company’s pursuit of product registration in Australia.

Quick facts: THC Global Group Ltd

Price: - AUD

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of THC Global Group Ltd named herein, including the promotion by the Company of THC Global Group Ltd in any Content on the Site, the Company...


Full interview: THC Global Group granted GMP Licence for Southport cannabis...

THC Global Group Limited (ASX:THC) chief executive officer Ken Charteris updates Proactive on being granted a licence to manufacture therapeutic goods for the company’s Southport Facility, known as a GMP Licence, by the Australian Therapeutic Goods Administration (TGA). This milestone...

on 29/1/20

2 min read